Fig. 9.

CsA promotes the anticancer activities of crizotinib in primary human NSCLC models. (a) 1 × 10⁵ human NSCLC cells were seeded in 6 well plate and cultured in ACL4 medium plus 5% FBS. 2 μM CsA and 2 μm crizotinib were added the next day. The number of cells were calculated every day for 6 days. (b) In vivo hollow fiber assay results. Crizotinib and CsA were administered by oral gavage at the dose of 30 mg/kg/day and 20 mg/kg/day respectively once daily for one week. The ATP content of each tube was measured by the addition of luciferin-luciferase. (c) Primary NSCLC cells were incubated with 2 μM CsA and 4 μm crizotinib for 48 h, after which they were examined for immunoblotting. All results were from 3 separated cell strains. c-Caspase 3 represented for cleaved caspase 3. Values of (a) were presented as mean ± SD and compared using one-way ANOVA. Values of (b) were presented as mean ± SD and compared using student's t-test. *** P < 0.001.